Evergreen Capital Management’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.04M Buy
9,033
+19
+0.2% +$2.04K 0.02% 494
2026
Q2
$784K Sell
9,014
-252
-3% -$15.2K 0.01% 657
2026
Q1
$374K Buy
9,266
+657
+8% +$24.6K 0.01% 980
2025
Q4
$300K Buy
8,609
+248
+3% +$19.5K 0.01% 1038
2025
Q3
$695K Buy
8,361
+755
+10% +$54.6K 0.02% 509
2025
Q2
$558K Buy
7,606
+448
+6% +$32.5K 0.02% 515
2025
Q1
$818K Buy
7,158
+265
+4% +$16.1K 0.03% 368
2024
Q4
$347K Buy
6,893
+181
+3% +$9.48K 0.01% 663
2024
Q3
$311K Buy
6,712
+48
+0.7% +$1.71K 0.01% 692
2024
Q2
$217K Buy
+6,664
New +$183K 0.01% 819
2024
Q1
– Sell
-6,651
Closed -$216K – 885
2023
Q4
$216K Buy
+6,651
New +$183K 0.01% 746

Other funds holding CORT

Evergreen Capital Management's CORT Position: Q3 2026 in Review

Evergreen Capital Management increased its Corcept Therapeutics (CORT) stake by 0.21% in Q3 2026, buying an estimated $2.04K and bringing the position to 9,033 shares worth $1.04M. The position accounts for 0.02% of the portfolio, ranked #494.

Evergreen Capital Management first reported a position in CORT in Q4 2023 and has held it in 11 quarters since. 403 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Evergreen Capital Management held 9,033 shares of Corcept Therapeutics worth $1.04M as of Q3 2026.
  • Evergreen Capital Management bought 19 Corcept Therapeutics shares in Q3 2026, an estimated $2.04K.
  • Corcept Therapeutics made up 0.02% of Evergreen Capital Management's portfolio in Q3 2026, its #494 holding.
  • Evergreen Capital Management first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 403 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Evergreen Capital Management's 13F filing for Q3 2026, filed 23 Oct 2026.